Results 261 to 270 of about 41,965 (298)

Nicotinic Receptors in the Medial Habenula to Interpeduncular Nucleus Pathway: Modulators of Reward, Aversion and Emotion. [PDF]

Eur J Neurosci
Ciscato M, Chouvaeff M, Mourot A.
europepmc   +1 more source

Correction to: 'Unravelling nicotinic receptor and ligand features underlying neonicotinoid knockdown actions on the malaria vector mosquito <i>Anopheles gambiae</i>' (2024), by Ito <i>et al.</i> [PDF]

Open Biol
Ito R, Kamiya M, Takayama K, Mori S, Matsumoto R, Takebayashi M, Ojima H, Fujimura S, Yamamoto H, Ohno M, Ihara M, Okajima T, Yamashita A, Colman F, Lycett GJ, Sattelle DB, Matsuda K.   +16 more
europepmc   +1 more source

Targeting GPR3 as a novel approach for nicotine cessation therapeutic development. [PDF]

Neuropsychopharmacology
Mogul AS, Laumann KN, Bautista M, Fowler JP, Blough BE, Gay EA, Fowler CD.   +6 more
europepmc   +1 more source

Non-neuronal cholinergic stimulation favors bone mass accrual. [PDF]

Front Physiol
Tamimi F, Eimar H, Alebrahim S, Abu-Nada L, Manickam G, Al Subaie AE, Tamimi I, Murshed M.   +7 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Nicotinic Agonists and Psychosis

Current Drug Target -CNS & Neurological Disorders, 2002
Schizophrenia patients have insufficient inhibitory processing of identical paired auditory stimuli. This deficient "auditory gating" is thought to have physiological relevance, and its severity correlates with certain measures of both positive and negative symptoms.
J K, Simosky, K E, Stevens, R, Freedman
openaire   +2 more sources

Neuronal nicotinic acetylcholine receptor agonists

Expert Opinion on Therapeutic Patents, 2004
Nicotinic acetylcholine receptors (nAChRs) consist of five protein subunits surrounding a central ion channel.
TOMA, LUCIO, BARLOCCO Daniela, GELAIN Arianna   +2 more
openaire   +3 more sources

Pharmacotherapy for tobacco cessation: Nicotine agonists, antagonists, and partial agonists

Current Oncology Reports, 2007
Nicotine replacement therapies (NRT) were the main pharmacologic option for treatment of nicotine dependence until the early 1990s, when controlled clinical trials confirmed the efficacy of bupropion, the first treatment not based on nicotine. Varenicline, a partial agonist at nicotine receptors, gained US regulatory approval in 2006 for smoking ...
Maher, Karam-Hage, Paul M, Cinciripini
openaire   +2 more sources

Neuronal Nicotinic Acetylcholine Receptor Agonists

Current Pharmaceutical Design, 1996
In contrast to the considerable effort over many years to design agonists of the muscanmc acetylcholine receptor, until recently little attention has been directed towards agonists of the nicotinic family of acetylcholine receptors (NAChRs). Nevertheless, the structure and function of NAChRs has been a topic of intense research for several decades ...
Ian A. McDonald, Jean-Michel Vernier, Nicholas Cosford, Janis Corey-Naeve   +3 more
openaire   +1 more source